
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4288387/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy. Circulation, 2014, 130, 484-495.	1.6	783
2	Hypertrophic Cardiomyopathy inÂAdulthood Associated With LowÂCardiovascular Mortality With Contemporary Management Strategies. Journal of the American College of Cardiology, 2015, 65, 1915-1928.	1.2	257
3	Hypertrophic Cardiomyopathy With LeftÂVentricular Apical Aneurysm. Journal of the American College of Cardiology, 2017, 69, 761-773.	1.2	252
4	Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. JAMA Cardiology, 2019, 4, 644.	3.0	222
5	Risk Stratification and Outcome of Patients With Hypertrophic Cardiomyopathy ≥60 Years of Age. Circulation, 2013, 127, 585-593.	1.6	200
6	How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality. JAMA Cardiology, 2016, 1, 98.	3.0	191
7	Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation, 2017, 136, 2420-2436.	1.6	183
8	Diagnosis and Evaluation of HypertrophicÂCardiomyopathy. Journal of the American College of Cardiology, 2022, 79, 372-389.	1.2	152
9	Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2015, 116, 757-764.	0.7	148
10	Low Operative Mortality Achieved With Surgical Septal Myectomy. Journal of the American College of Cardiology, 2015, 66, 1307-1308.	1.2	146
11	Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2016, 67, 1399-1409.	1.2	142
12	Prevalence and Clinical Profile of Myocardial Crypts in Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Imaging, 2012, 5, 441-447.	1.3	138
13	Left Ventricular Unloading BeforeÂReperfusion Promotes FunctionalÂRecovery After AcuteÂMyocardialÂInfarction. Journal of the American College of Cardiology, 2018, 72, 501-514.	1.2	138
14	Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. Circulation, 2016, 133, 62-73.	1.6	135
15	Management of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2022, 79, 390-414.	1.2	129
16	Clinical Spectrum and ManagementÂofÂHeart Failure inÂHypertrophicÂCardiomyopathy. JACC: Heart Failure, 2018, 6, 353-363.	1.9	105
17	Significance of False Negative Electrocardiograms in Preparticipation Screening of Athletes for Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2012, 110, 1027-1032.	0.7	92
18	Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction. Journal of the American College of Cardiology, 2020, 75, 3033-3043.	1.2	82

#	Article	IF	CITATIONS
19	Comparing CMR Mapping Methods andÂMyocardial Patterns Toward HeartÂFailure Outcomes in NonischemicÂDilated Cardiomyopathy. JACC: Cardiovascular Imaging, 2019, 12, 1659-1669.	2.3	80
20	Global Burden of HypertrophicÂCardiomyopathy. JACC: Heart Failure, 2018, 6, 376-378.	1.9	77
21	Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. Annals of Cardiothoracic Surgery, 2017, 6, 353-363.	0.6	75
22	Advanced Heart Failure With Preserved Systolic Function in Nonobstructive Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2014, 7, 967-975.	1.6	71
23	Role of Exercise Testing in HypertrophicÂCardiomyopathy. JACC: Cardiovascular Imaging, 2017, 10, 1374-1386.	2.3	68
24	Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	63
25	Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2015, 116, 436-441.	0.7	62
26	Significance of left ventricular apical–basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2706-2713.	1.0	61
27	Three-dimensional Deep Convolutional Neural Networks for Automated Myocardial Scar Quantification in Hypertrophic Cardiomyopathy: A Multicenter Multivendor Study. Radiology, 2020, 294, 52-60.	3.6	58
28	CMR With Late Gadolinium Enhancement in Genotype Positive–Phenotype Negative Hypertrophic Cardiomyopathy. JACC: Cardiovascular Imaging, 2012, 5, 119-122.	2.3	55
29	Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience. Journal of the American Heart Association, 2016, 5, .	1.6	54
30	Papillary Muscle Insertion Directly into the Anterior Mitral Leaflet in Hypertrophic Cardiomyopathy, Its Identification and Cause of Outflow Obstruction by Cardiac Magnetic Resonance Imaging, and Its Surgical Management. American Journal of Cardiology, 2013, 111, 1677-1679.	0.7	53
31	Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. Nature Communications, 2021, 12, 873.	5.8	53
32	The Role of Cardiac MRI in the Diagnosis and Risk Stratification of Hypertrophic Cardiomyopathy. Arrhythmia and Electrophysiology Review, 2016, 5, 197.	1.3	50
33	Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005820.	2.1	50
34	How to Image Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Imaging, 2017, 10, .	1.3	49
35	Why we need more septal myectomy surgeons: An emerging recognition. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 1681-1685.	0.4	48
36	Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy. Circulation Research, 2019, 125, 370-378.	2.0	47

#	Article	IF	CITATIONS
37	What Do Patients With Hypertrophic Cardiomyopathy Die from?. American Journal of Cardiology, 2016, 117, 434-435.	0.7	46
38	Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2017, 120, 2256-2264.	0.7	45
39	Survival Following Alcohol Septal Ablation or Septal Myectomy for PatientsÂWith Obstructive HypertrophicÂCardiomyopathy. Journal of the American College of Cardiology, 2022, 79, 1647-1655.	1.2	45
40	Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator. Heart Rhythm, 2021, 18, 1012-1023.	0.3	44
41	Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2017, 10, e003689.	1.6	43
42	Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy. Circulation, 2019, 139, 830-833.	1.6	43
43	The Hypertrophic Cardiomyopathy Phenotype Viewed Through the PrismÂofÂMultimodality Imaging. JACC: Cardiovascular Imaging, 2020, 13, 2002-2016.	2.3	42
44	Impact of Advanced Therapies for Improving Survival to Heart Transplant in Patients with Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2018, 121, 986-996.	0.7	41
45	Progression of Myocardial Fibrosis in Hypertrophic Cardiomyopathy. JACC: Cardiovascular Imaging, 2021, 14, 947-958.	2.3	41
46	Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes. Circulation: Cardiovascular Interventions, 2019, 12, e007673.	1.4	39
47	Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy and Defibrillators: Triggers, Treatment, and Implications. Journal of Cardiovascular Electrophysiology, 2017, 28, 531-537.	0.8	38
48	Perspectives on the Overall Risks of Living With Hypertrophic Cardiomyopathy. Circulation, 2017, 135, 2317-2319.	1.6	35
49	Clinical Profile of Nonresponders to Surgical Myectomy with Obstructive Hypertrophic Cardiomyopathy. American Journal of Medicine, 2018, 131, e235-e239.	0.6	35
50	Occurrence and Natural History of Clinically Silent Episodes of Atrial Fibrillation in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2017, 119, 1862-1865.	0.7	34
51	Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (β-Myosin Heavy) Tj E Cardiovascular Imaging, 2017, 10, .	TQq1 1 0.7 1.3	784314 rgBT 31
52	Association Between Race and Clinical Profile of Patients Referred for Hypertrophic Cardiomyopathy. Circulation, 2018, 137, 1973-1975.	1.6	31
53	Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy. American Journal of Medicine, 2018, 131, 200.e1-200.e8.	0.6	31
54	Velocity Vector Imaging in the Measurement of Left Ventricular Myocardial Mechanics on Cardiac Magnetic Resonance Imaging: Correlations with Echocardiographically Derived Strain Values. Journal of the American Society of Echocardiography, 2013, 26, 1153-1162.	1.2	29

#	Article	IF	CITATIONS
55	Clinical Spectrum and Management Implications of Left Ventricular Outflow Obstruction With Mild Ventricular Septal Thickness in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2018, 122, 1409-1420.	0.7	28
56	Efficacy of Combined Cox-Maze IV and Ventricular Septal Myectomy for Treatment of Atrial Fibrillation in Patients With Obstructive Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2020, 125, 120-126.	0.7	27
57	Return to Play for Athletes After COVID-19 Infection. JAMA Cardiology, 2021, 6, 997.	3.0	25
58	Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2019, 123, 1859-1862.	0.7	24
59	LeftÂventricular apical aneurysm in hypertrophic cardiomyopathy as a risk factor for sudden death at any age. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1031-1033.	0.5	22
60	Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008123.	2.1	21
61	Improved Quantification of Myocardium Scar in Late Gadolinium Enhancement Images: Deep Learning Based Image Fusion Approach. Journal of Magnetic Resonance Imaging, 2021, 54, 303-312.	1.9	20
62	Prognostic role of left ventricular apical aneurysm in hypertrophic cardiomyopathy: A systematic review and meta-analysis. International Journal of Cardiology, 2021, 332, 127-132.	0.8	20
63	Prediction and Prevention of Sudden Death in Young Patients (<20 years) With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2020, 128, 75-83.	0.7	19
64	Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored $\hat{a} \in \$ Until Now. American Journal of Medicine, 2017, 130, 119-123.	0.6	17
65	Hypertrophic Cardiomyopathy and Sudden Death Initially Identified at Autopsy. American Journal of Cardiology, 2020, 127, 139-141.	0.7	16
66	Impact of Effective Management Strategies on Patients With the Most Extreme Phenotypic Expression of Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2019, 124, 113-121.	0.7	15
67	Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy. European Journal of Preventive Cardiology, 2020, 27, 1821-1831.	0.8	15
68	Return to Play for Athletes After Coronavirus Disease 2019 Infection—Making High-Stakes Recommendations as Data Evolve. JAMA Cardiology, 2021, 6, 136.	3.0	14
69	Usefulness of Global Longitudinal Strain to Predict Heart Failure Progression in Patients With Nonobstructive Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2021, 151, 86-92.	0.7	14
70	Hypertrophic Cardiomyopathy: New Concepts and Therapies. Annual Review of Medicine, 2022, 73, 363-375.	5.0	14
71	Plasma Proteomic Profiling in Hypertrophic Cardiomyopathy Patients before and after Surgical Myectomy Reveals Post-Procedural Reduction in Systemic Inflammation. International Journal of Molecular Sciences, 2021, 22, 2474.	1.8	13
72	Development and Validation of a Clinical Predictive Model for Identifying Hypertrophic Cardiomyopathy Patients at Risk for Atrial Fibrillation: The HCM-AF Score. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009796.	2.1	13

#	Article	IF	CITATIONS
73	Asymptomatic Young Man with Danon Disease. Texas Heart Institute Journal, 2014, 41, 332-334.	0.1	12
74	Machine Learning for Predicting Heart Failure Progression in Hypertrophic Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2021, 8, 647857.	1.1	11
75	Outcomes Over Follow-up ≥10 Years After Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2022, 163, 91-97.	0.7	11
76	Importance of newer cardiac magnetic resonance–based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study. Heart Rhythm, 2022, 19, 782-789.	0.3	11
77	Surgical Approaches to Hypertrophic Obstructive Cardiomyopathy. Seminars in Thoracic and Cardiovascular Surgery, 2018, 30, 125-128.	0.4	10
78	Intraoperative Provocative Testing in Patients with Obstructive Hypertrophic Cardiomyopathy Undergoing Septal Myectomy. Journal of the American Society of Echocardiography, 2020, 33, 182-190.	1.2	10
79	Adult Monozygotic Twins With Hypertrophic Cardiomyopathy and Identical Disease Expression and Clinical Course. American Journal of Cardiology, 2020, 127, 135-138.	0.7	10
80	Altered intercellular communication and extracellular matrix signaling as a potential disease mechanism in human hypertrophic cardiomyopathy. Scientific Reports, 2022, 12, 5211.	1.6	10
81	What Causes Hypertrophic Cardiomyopathy?. American Journal of Cardiology, 2022, 179, 74-82.	0.7	10
82	Underappreciated occurrence of discrete subaortic membranes producing left ventricular outflow obstruction in hypertrophic cardiomyopathy. Echocardiography, 2017, 34, 1247-1249.	0.3	9
83	Coronary Embolization in Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm. American Journal of Cardiology, 2015, 115, 1318-1319.	0.7	8
84	Thinking Outside the Heart to Treat Atrial Fibrillation in Hypertrophic Cardiomyopathy. Journal of the American Heart Association, 2020, 9, e016260.	1.6	7
85	Benefit of Cardiac Resynchronization Therapy in End-Stage Nonobstructive Hypertrophic Cardiomyopathy. JACC: Clinical Electrophysiology, 2019, 5, 131-133.	1.3	6
86	Hypertrophic Cardiomyopathy: Is a â€~Cure' Coming Or Is It Already Here?. American Journal of Medicine, 2020, 133, 886-888.	0.6	6
87	Back to the future: Predicting sudden death in hypertrophic cardiomyopathy relying on individual risk markers and physician judgment without mathematical scoring. Heart Rhythm, 2021, 18, 148-150.	0.3	6
88	Echocardiographic profiles in hypertrophic cardiomyopathy: imaging beyond the septum and systolic anterior motion. Journal of Animal Science and Technology, 2015, 2, E1-E7.	0.8	6
89	Impact of Comorbidities on Atrial Fibrillation and Sudden Cardiac Death in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2021, , .	0.8	6
90	Future Role of New Negative Inotropic Agents in the Era of Established Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. Journal of the American Heart Association, 2022, 11, e024566.	1.6	6

#	Article	IF	CITATIONS
91	Changing Demographics in Hypertrophic Cardiomyopathy and Implications for Management: Clinical Research. American Journal of Medicine, 2022, 135, 1244-1246.	0.6	6
92	Ventricular Septal Myectomy Decreases Long-Term Risk for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2022, 179, 70-73.	0.7	6
93	Adipositas Cordis. Circulation, 2010, 122, 2212-2214.	1.6	5
94	Hypertrophic Cardiomyopathy in "Real-World―Community Cardiology Practice. American Journal of Cardiology, 2020, 125, 1398-1403.	0.7	5
95	Is Regression of Left Ventricular Hypertrophy Really a Good Thing for Patients With Hypertrophic Cardiomyopathy?: The Emerging Mavacamten Story. American Journal of Cardiology, 2021, 147, 145-146.	0.7	5
96	Clinical Diagnosis of Hypertrophic Cardiomyopathy Over Time in the United States (A Population-Based) Tj ETQ	q0 0 0 rgB	Г/Qverlock 10
97	Cardiovascular Diseases That Have Emerged From the Darkness. Journal of the American Heart Association, 2021, 10, e021095.	1.6	5
98	Evidence for Left Ventricular Outflow Tract Obstruction With Minimal Septal Hypertrophy. Circulation: Cardiovascular Imaging, 2015, 8, e003588.	1.3	4
99	The ESC Risk Score Is Less Reliable than ACC/AHA Risk Factors in Hypertrophic Cardiomyopathy: When Sensitivity Trumps Specificity. Canadian Journal of Cardiology, 2019, 35, 1626-1628.	0.8	4
100	Single Coil Implantable Cardioverter Defibrillator Leads in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2020, 125, 1896-1900.	0.7	4
101	Low Risk of Hypertrophic Cardiomyopathy With Contemporary Management Strategies Implemented in Non-Referral Regional Community-Based Practices. American Journal of Cardiology, 2021, 142, 130-135.	0.7	4
102	Evaluating Histopathology to Improve Our Understanding of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2021, 77, 2171-2173.	1.2	4
103	Anatomic validation of late gadolinium enhancement as evidence of myocardial scarring in LAMP2 cardiomyopathy. European Heart Journal, 2017, 38, 2444-2444.	1.0	3
104	Letter by Maron et al Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)― Circulation, 2019, 139, 1557-1558.	1.6	3
105	Cardiac Sarcoidosis Mimicking Hypertrophic Cardiomyopathy. JACC: Case Reports, 2020, 2, 2060-2062.	0.3	3
106	Myocardial Bridge or Something Else?. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 332-337.	0.6	3
107	What is the best imaging test for patients with hypertrophic cardiomyopathy? It depends on the clinical question!. Journal of Cardiovascular Computed Tomography, 2014, 8, 438-441.	0.7	2
108	Achieving Extended Longevity and Quality of Life for Senior Patients With Hypertrophic Cardiomyopathy: What Is Possible. American Journal of Medicine, 2017, 130, 1236-1237.	0.6	2

#	Article	IF	CITATIONS
109	Response by Rowin et al to Letter Regarding Article, "Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy― Circulation, 2018, 137, 2541-2542.	1.6	2
110	Increasing evidence that risk scores underperform in predicting sudden death in hypertrophic cardiomyopathy. Heart, 2019, 105, 1850-1851.	1.2	2
111	Chronic Heart Failure Is Infrequently Associated With Renal Dysfunction in Hypertrophic Cardiomyopathy. Journal of Cardiac Failure, 2019, 25, 690-692.	0.7	2
112	Hypertrophic cardiomyopathy with left ventricular apical aneurysm: the newest high-risk phenotype. European Heart Journal Cardiovascular Imaging, 2020, 21, 1351-1352.	0.5	2
113	Reply. Journal of the American College of Cardiology, 2020, 76, 1913.	1.2	2
114	Fixed, highâ€volume alcohol dose for septal ablation: High risk with no benefit. Catheterization and Cardiovascular Interventions, 2020, 95, 1219-1220.	0.7	2
115	Combined alcohol septal ablation and transcatheter aortic valve replacement: Drunk and playing with fire. Catheterization and Cardiovascular Interventions, 2020, 95, 838-839.	0.7	2
116	Concerns About the HCM Risk-Kids Study. JAMA Cardiology, 2020, 5, 362.	3.0	2
117	After 60 Years Hypertrophic Cardiomyopathy is Finally Recognized as a Contemporary Treatable Disease With Low Mortality and Morbidity, But is This Paradigm Under-Recognized in the Literature?. American Journal of Cardiology, 2021, 142, 136-137.	0.7	2
118	Standards for writing Society for Cardiovascular Magnetic Resonance (SCMR) endorsed guidelines, expert consensus, and recommendations: a report of the publications committee. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 129.	1.6	2
119	Transcatheter Mitral Intervention Relieves Dynamic Outflow Obstruction and Reduces Cardiac Workload in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009171.	1.6	2
120	Characteristics of Patients With Obstructive Hypertrophic Cardiomyopathy in Real-World Community-Based Cardiovascular Practices. American Journal of Cardiology, 2022, 174, 120-125.	0.7	2
121	Response to Letter Regarding Article, "Prevalence and Clinical Profile of Myocardial Crypts in Hypertrophic Cardiomyopathy― Circulation: Cardiovascular Imaging, 2012, 5, .	1.3	1
122	A Case of Multiple Ventricular Gradients. Journal of Cardiothoracic and Vascular Anesthesia, 2018, 32, 1829-1832.	0.6	1
123	Editorial commentary: Role of cardiac magnetic resonance imaging in the evaluation of amyloidosis. Trends in Cardiovascular Medicine, 2019, 29, 95-96.	2.3	1
124	Two Tales of Cardiomyopathy: Underscore for One Health Initiative. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 2811-2814.	0.6	1
125	Abstract 17402: Single Nuclei RNA-sequencing of Human Hypertrophic Cardiomyopathy Myectomy Samples Reveals Common Novel Mechanisms of Pathogenesis and Potential Therapeutic Targets Regardless of Genotype. Circulation, 2020, 142, .	1.6	1
126	Cats Have Nine Lives but This Hypertrophic Cardiomyopathy Patient Has Had Ten (So Far). American Journal of Cardiology, 2022, 168, 163-165.	0.7	1

#	Article	IF	CITATIONS
127	Sixty-Year Evolution of Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy with Insights From the Historic NIH Surgical Experience to Present. American Journal of Cardiology, 2022, , .	0.7	1
128	Global Dissemination and Implementation of Contemporary Management Principles for Hypertrophic Cardiomyopathy and Role of the International HCM Summit. American Journal of Cardiology, 2022, 172, 146-149.	0.7	1
129	Abstract 12214: Characterization of latrogenic Left Bundle Branch Block After Septal Myectomy for Hypertrophic Cardiomyopathy. Circulation, 2021, 144, .	1.6	1
130	Reply. JACC: Heart Failure, 2018, 6, 807-808.	1.9	0
131	Editorial commentary: Hold your horses (and mice, rats, and cats): How relevant really are animal models of hypertrophic cardiomyopathy?. Trends in Cardiovascular Medicine, 2021, 31, 32-33.	2.3	0
132	Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy. , 2020, , 101-102.		0
133	Abstract 15961: Multicenter Prospective Prevention of Sudden Death in High Risk Patients Utilizing Enhanced ACC/AHA Risk Model. Circulation, 2020, 142, .	1.6	0
134	Abstract 15889: The Role of Physical Deconditioning in Distinguishing Hypertrophic Cardiomyopathy From Athlete's Heart. Circulation, 2020, 142, .	1.6	0
135	Abstract 17341: Obesity is Associated With Progressive Heart Failure in Hypertrophic Cardiomyopathy. Circulation, 2020, 142, .	1.6	0
136	Abstract 16082: Machine Learning to Improve Left Ventricular Scar Quantification in Hypertrophic Cardiomyopathy Patients. Circulation, 2020, 142, .	1.6	0
137	Congenital Left Ventricular Diverticulum Complicated by Cardioembolic Stroke. Case, 2022, 6, 55-58.	0.1	0
138	ls surgical myectomy challenged by emergence of novel drug therapy with mavacamten?. Asian Cardiovascular and Thoracic Annals, 2022, , 021849232210744.	0.2	0
139	Winter Is Coming. JACC: Case Reports, 2022, 4, 99-101.	0.3	0
140	Abstract 9755: Impact of Outflow Obstruction and Septal Myectomy on Long Term Risk of New Onset Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation, 2021, 144, .	1.6	0
141	Clinical Characteristics and Healthcare Resource Utilization among Patients with Obstructive Hypertrophic Cardiomyopathy Treated in a Range of Settings in the United States. Journal of Clinical Medicine, 2022, 11, 3898.	1.0	ο